Coherus, Amgen End Patent War Over Humira Biosimilar
Coherus BioSciences Inc. and biopharmaceutical giant Amgen Inc. agreed to end a patent infringement lawsuit in Delaware federal court Tuesday over Amgen's biosimilar formulation of the popular immunosuppressant drug Humira....To view the full article, register now.
Already a subscriber? Click here to view full article